Company
Janssen Biotech, Inc.
20 Case(s) (Last 5 Years)
Patents Prosecuted
| Application number | Title of the patent | IPC | Filing Date | Decision Date |
|---|---|---|---|---|
| 18052174 | METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF BCMAXCD3 BISPECIFIC ANTIBODIES | A61K, C07K, A61P | Nov 1, 2022 | |
| 17968675 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS | C12N | Oct 17, 2022 | |
| 17932117 | Fibronectin Type III Domain Based Scaffold Compositions, Methods and Uses | C40B, C07K | Sep 13, 2022 | |
| 17931633 | Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody | C07K, A61P | Sep 12, 2022 | |
| 17822438 | Substituted aminopyridine compounds as EGFR inhibitors | C07D | Aug 25, 2022 | Apr 1, 2024 |
| 17822450 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | C07D | Aug 25, 2022 | |
| 17822443 | 5-MEMBERED HETEROARYL-CONTAINING AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | C07D | Aug 25, 2022 | |
| 17895312 | ANTI-PSMA RADIOCONJUGATES AND USES THEREOF | A61K | Aug 24, 2022 | |
| 17895295 | ANTI-PSMA ANTIBODIES AND USES THEREOF | A61P, A61K, C07K | Aug 24, 2022 | |
| 17817295 | COMBINATION THERAPIES AND PATIENT STRATIFICATION WITH BISPECIFIC ANTI-EGFR/C-MET ANTIBODIES | C07K | Aug 2, 2022 | |
| 17854211 | TREATMENTS FOR DIFFUSE LARGE B-CELL LYMPHOMA | A61P, A61K | Jun 29, 2022 | |
| 17844484 | MATERIALS AND METHODS FOR HINGE REGIONS IN FUNCTIONAL EXOGENOUS RECEPTORS | G01N, C07K | Jun 19, 2022 | |
| 17835671 | NUCLEIC ACID CONSTRUCTS ENCODING KALLIKREIN-2 FUSION PROTEIN AND VECTORS, PREPARATIONS OF CELLS, AND METHODS OF USE THEREOF | A61P, C12N | Jun 7, 2022 | |
| 17825244 | ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-CD79B ANTIBODIES | C07K, G01N | May 25, 2022 | |
| 17752892 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROSTATE CANCER | A61K, A61P | May 24, 2022 | |
| 17748629 | Method of Treating Inflammatory Bowel Disease with a Combination Therapy of Antibodies to IL-23 and TNF Alpha | A61P, C07K, A61K | May 18, 2022 | |
| 17747346 | Methods for Identifying Cancer Patients for Combination Treatment | C07K, C12Q, A61P, A61K, G01N | May 17, 2022 | |
| 17742076 | METHODS AND COMPOSITIONS FOR MONITORING THE TREATMENT OF RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA | G01N | May 10, 2022 | |
| 17732420 | CD137 BINDING FIBRONECTIN TYPE III DOMAINS | C12N, G01N, A61P, C07K | Apr 27, 2022 | |
| 17712661 | CALR AND JAK2 T-CELL RECEPTORS | C12N, C07K | Apr 3, 2022 |